Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects. Credit: Arcus Biosciences Subscribe now Already have an account? Sign in.
